Global Orphan Indication Treatment Market Research Report 2022

An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients.The classification of certain diseases, and the medicines that treat them, as "orphan" is a matter of public policy in many countries . Given the nature of the enormous economic resources required for medical research , these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance.In the United States and the European Union , orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive , few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research.
Due to the COVID-19 pandemic, the global Orphan Indication Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Orphan Indication Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Orphan Indication Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Biologics accounting for % of the Orphan Indication Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Orphan Indication Treatment include Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, Pfizer, Amgen, Sanofi, AstraZeneca and Takeda, etc. In terms of revenue, the global 3 largest players have a % market share of Orphan Indication Treatment in 2021.
This report focuses on Orphan Indication Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Orphan Indication Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Orphan Indication Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Biologics
Non-Biologics
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Sales
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly